Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2

Oncotarget

Volumn 7, Issue 6, 2016, Pages 6436-6447

  Xie, Junran ^a   Xiao, Dongju ^b,c   Xu, Yun ^b,c   Zhao, Jinning ^a   Jiang, Li ^a   Hu, Xuming ^b,c   Zhang, Yaping ^b,c   Yu, Lina ^d  

^a ZHEJIANG UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c Jiangsu Province Key Laboratory of Anesthetic and Analgesic Application Technology   (China)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cannabinoid receptor; Immune response; Immunity; Immunology and microbiology section; Inflammation; Mesenchymal stem cells; Pain; Tetrahydrocannabinol

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TETRAHYDROCANNABINOL; CANNABINOID RECEPTOR AGONIST; CYTOKINE; DRONABINOL; MESSENGER RNA;

ADULT; ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL MATURATION; CHRONIC CONSTRICTION INJURY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MECHANICAL ALLODYNIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROGLIA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THERMAL HYPERALGESIA; UPREGULATION; AGONISTS; ANIMAL; APOPTOSIS; BONE MARROW; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; MESENCHYMAL STROMA CELL; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCIATIC NERVE; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW; CANNABINOID RECEPTOR AGONISTS; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DRONABINOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HYPERALGESIA; IMMUNOMODULATION; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCIATIC NERVE; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84980717603     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7042     Document Type: Article

References (50)

1. Staud R and Koo EB. Are cannabinoids a new treatment option for pain in patients with fibromyalgia? Nature clinical practice Rheumatology. 2008; 4:348-349.
2. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA and McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Bmj. 2001; 323:13-16.
3. Karst M and Wippermann S. Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective. Expert opinion on investigational drugs. 2009; 18:125-133.
4. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S and Bouhassira D. Are oral cannabinoids safe and effective in refractory neuropathic pain? European journal of pain. 2004; 8:173-177.
5. Michalski CW, Laukert T, Sauliunaite D, Pacher P, Bergmann F, Agarwal N, Su Y, Giese T, Giese NA, Batkai S, Friess H and Kuner R. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology. 2007; 132:1968-1978.
6. Lever IJ and Rice AS. Cannabinoids and pain. Handbook of experimental pharmacology. 2007:265-306.
7. Rice AS. Cannabinoids and pain. Current opinion in investigational drugs. 2001; 2:399-414.
8. Fine PG and Rosenfeld MJ. Cannabinoids for neuropathic pain. Current pain and headache reports. 2014; 18:451.
9. Davis MP. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert opinion on investigational drugs. 2014; 23:1123-1140.
10. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L and James I. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 2001; 92:91-100.
11. Rahn EJ and Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2009; 6:713-737.
12. Walker JM, Strangman NM and Huang SM. Cannabinoids and pain. Pain research & management : the journal of the Canadian Pain Society = journal de la societe canadienne pour le traitement de la douleur. 2001; 6:74-79.
13. Hung O, Lynch ME and Clark AJ. Cannabinoids and pain management. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 2006; 53:743-746.
14. Grotenhermen F. Cannabinoids in pain management. Cannabinoid receptor agonists will soon find their place in modern medicine. Bmj. 2001; 323:1250-1251.
15. Franchi S, Castelli M, Amodeo G, Niada S, Ferrari D, Vescovi A, Brini AT, Panerai AE and Sacerdote P. Adult stem cell as new advanced therapy for experimental neuropathic pain treatment. BioMed research international. 2014; 2014:470983.
16. Uccelli A and de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Annals of the New York Academy of Sciences. 2015.
17. Chen H, Min XH, Wang QY, Leung FW, Shi L, Zhou Y, Yu T, Wang CM, An G, Sha WH and Chen QK. Pre-activation of mesenchymal stem cells with TNF-alpha, IL-1beta and nitric oxide enhances its paracrine effects on radiation-induced intestinal injury. Scientific reports. 2015; 5:8718.
18. Liu Y, Zhang R, Yan K, Chen F, Huang W, Lv B, Sun C, Xu L, Li F and Jiang X. Mesenchymal stem cells inhibit lipopolysaccharide-induced inflammatory responses of BV2 microglial cells through TSG-6. Journal of neuroinflammation. 2014; 11:135.
19. Bertolo A, Thiede T, Aebli N, Baur M, Ferguson SJ and Stoyanov JV. Human mesenchymal stem cell co-culture modulates the immunological properties of human intervertebral disc tissue fragments in vitro. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2011; 20:592-603.
20. Schafer S, Berger JV, Deumens R, Goursaud S, Hanisch UK and Hermans E. Influence of intrathecal delivery of bone marrow-derived mesenchymal stem cells on spinal inflammation and pain hypersensitivity in a rat model of peripheral nerve injury. Journal of neuroinflammation. 2014; 11:157.
21. Xiong W, Cui T, Cheng K, Yang F, Chen SR, Willenbring D, Guan Y, Pan HL, Ren K, Xu Y and Zhang L. Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycine receptors. The Journal of experimental medicine. 2012; 209:1121-1134.
22. Holdcroft A and Patel P. Cannabinoids and pain relief. Expert review of neurotherapeutics. 2001; 1:92-99.
23. Ahmed AI, van den Elsen GA, van der Marck MA and Olde Rikkert MG. Cannabinoids for pain in dementia: the good, the bad, and the ugly. Journal of the American Geriatrics Society. 2014; 62:1001-1002.
24. Sacerdote P, Franchi S, Moretti S, Castelli M, Procacci P, Magnaghi V and Panerai AE. Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2013; 8:202-211.
25. Beaulieu P. Cannabinoids for postoperative pain. Anesthesiology. 2007; 106:397; author reply 397-398.
26. Igon'kina SI, Churiukanov MV, Churiukanov VV and Kukushkin ML. [Analgesic effects of cannabinoids on central pain syndrome]. Patologicheskaia fiziologiia i eksperimental'naia terapiia. 2011:51-54.
27. Sessle BJ. Are cannabinoids effective for orofacial pain states? Journal of oral & facial pain and headache. 2015; 29:5-6.
28. Sanchez Robles EM, Bagues Arias A and Martin Fontelles MI. Cannabinoids and muscular pain. Effectiveness of the local administration in rat. European journal of pain. 2012; 16:1116-1127.
29. Ashton JC and Milligan ED. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Current opinion in investigational drugs. 2008; 9:65-75.
30. Ware M and Beaulieu P. Cannabinoids for the treatment of pain: an update on recent clinical trials. Pain research & management : the journal of the Canadian Pain Society = journal de la societe canadienne pour le traitement de la douleur. 2005; 10 Suppl A:27A-30A.
31. Lynch ME and Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British journal of clinical pharmacology. 2011; 72:735-744.
32. Chen L, Huang H, Sharma HS, Zuo H and Sanberg PR. Cell transplantation as a pain therapy targets both analgesia and neural repair. Cell transplantation. 2013; 22 Suppl 1:S11-19.
33. Yu H, Fischer G, Ebert AD, Wu HE, Bai X and Hogan QH. Analgesia for neuropathic pain by dorsal root ganglion transplantation of genetically engineered mesenchymal stem cells: initial results. Molecular pain. 2015; 11:5.
34. Siniscalco D, Giordano C, Galderisi U, Luongo L, Alessio N, Di Bernardo G, de Novellis V, Rossi F and Maione S. Human mesenchymal stem cells as novel neuropathic pain tool. Journal of stem cells & regenerative medicine. 2010; 6:127.
35. Besalti O, Can P, Akpinar E, Aktas Z, Elcin AE and Elcin YM. Intraspinal Transplantation of Autologous Neurogenically-Induced Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Paraplegic Dogs without Deep Pain Perception Secondary to Intervertebral Disk Disease. Turkish neurosurgery. 2015; 25:625-632.
36. Galve-Roperh I, Chiurchiu V, Diaz-Alonso J, Bari M, Guzman M and Maccarrone M. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Progress in lipid research. 2013; 52:633-650.
37. Gowran A, McKayed K and Campbell VA. The cannabinoid receptor type 1 is essential for mesenchymal stem cell survival and differentiation: implications for bone health. Stem cells international. 2013; 2013:796715.
38. Sun YX, Xu AH, Yang Y, Zhang JX and Yu AW. Activation of cannabinoid receptor 2 enhances osteogenic differentiation of bone marrow derived mesenchymal stem cells. BioMed research international. 2015; 2015:874982.
39. Rossi F, Bernardo ME, Bellini G, Luongo L, Conforti A, Manzo I, Guida F, Cristino L, Imperatore R, Petrosino S, Nobili B, Di Marzo V, Locatelli F and Maione S. The cannabinoid receptor type 2 as mediator of mesenchymal stromal cell immunosuppressive properties. PloS one. 2013; 8:e80022.
40. Yang L, Li FF, Han YC, Jia B and Ding Y. Cannabinoid receptor CB2 is involved in tetrahydrocannabinol-induced anti-inflammation against lipopolysaccharide in MG-63 cells. Mediators of inflammation. 2015; 2015:362126.
41. Lynch ME and Ware MA. Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2015; 10:293-301.
42. Da S and Takahashi RN. SR 141716A prevents delta 9-tetrahydrocannabinol-induced spatial learning deficit in a Morris-type water maze in mice. Progress in neuro-psychopharmacology & biological psychiatry. 2002; 26:321-325.
43. D'Souza DC, Sewell RA and Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. European archives of psychiatry and clinical neuroscience. 2009; 259:413-431.
44. Huang P, Liu-Chen LY and Kirby LG. Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze. Neuroscience letters. 2010; 475:165-168.
45. Stern CA, Gazarini L, Vanvossen AC, Zuardi AW, Galve-Roperh I, Guimaraes FS, Takahashi RN and Bertoglio LJ. Delta9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2015; 25:958-965.
46. Stewart AM and Kalueff AV. The behavioral effects of acute Delta(9)-tetrahydrocannabinol and heroin (diacetylmorphine) exposure in adult zebrafish. Brain research. 2014; 1543:109-119.
47. Molina-Holgado F, Pinteaux E, Heenan L, Moore JD, Rothwell NJ and Gibson RM. Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Molecular and cellular neurosciences. 2005; 28:189-194.
48. Ozaita A, Puighermanal E and Maldonado R. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. Journal of neurochemistry. 2007; 102:1105-1114.
49. Sanchez MG, Ruiz-Llorente L, Sanchez AM and Diaz-Laviada I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cellular signalling. 2003; 15:851-859.
50. Franchi S, Valsecchi AE, Borsani E, Procacci P, Ferrari D, Zalfa C, Sartori P, Rodella LF, Vescovi A, Maione S, Rossi F, Sacerdote P, Colleoni M and Panerai AE. Intravenous neural stem cells abolish nociceptive hypersensitivity and trigger nerve regeneration in experimental neuropathy. Pain. 2012; 153:850-861.